I am a
Home I AM A Search Login

Papers of the Week

2022 Dec 29

Int J Dermatol

Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa.


Nosrati A, Torpey MCE, Shokrian N, Ch'en PY, Andriano TM, Benesh G, Heibel HD, Hosgood DH, Campton KL, Cohen SR
Int J Dermatol. 2022 Dec 29.
PMID: 36582044.


Adalimumab is the only FDA-approved biologic for hidradenitis suppurativa (HS). In the setting of increasing obesity rates worldwide, the relationship between adalimumab efficacy for HS and BMI is essential to understand. We assessed this relationship through markers of disease severity and inflammation.